Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma

Tanaka, Yasuhito; Mukaide, Motokazu; Orito, Etsuro; Yuen, Man‐Fung; Ito, Kiyoaki; Kurbanov, Fuat; Sugauchi, Fuminaka; Asahina, Yasuhiro; Izumi, Namiki; Kato, Masaaki; Lai, Ching–Lung; Ueda, Ryuzo; Mizokami, Masashi

doi:10.1016/j.jhep.2006.06.018

Cited by 119 publications

(117 citation statements)

References 44 publications

(57 reference statements)

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…These 'hot-spot' mutations are located in the carboxy functional region, and thus might be associated with the transactivating function of the X protein [32]. Previous studies also reported that other amino acid substitutions, such as A36T, P38S, A44L, and H94Y were significantly associated with the risk of HCC [11,15,33,34]. However, the prevalence of these mutations, except A36T, was found to be relatively low in our study and there was no significant difference in their prevalence between the HCC and non-HCC group.…”

Section: Discussionmentioning

confidence: 97%

“…These dual mutants have been reported in up to 50-80% of patients with HBeAg-negative chronic hepatitis B in Europe and Asia [6], and have been implicated in HCC development [7][8][9]. Apart from these variants, other mutations, such as T1753C/A/G in the BCP region and C1653T in the enhancer II region (EnhII) have become increasingly recognized as being associated with the outcome of chronic HBV infection, including HCC development [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Purpose To evaluate the sequence variations in the enhancer II (EnhII)/basal core promotor (BCP)/precore (PC) and X genes of hepatitis B virus (HBV) in Thai patients with hepatocellular carcinoma (HCC) by conducting a cross-sectional case-control study. Methods As much as 60 patients with HCC and 60 patients without HCC, who were matched for sex, age, hepatitis B e antigen (HBeAg) status, and HBV genotype, were included. Viral mutations in the EnhII/BCP/PC and X regions were characterized by direct sequencing in serum samples.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…For instance, many studies have revealed that the double mutation in BCP (A1762T/G1764A) is associated with an increased risk of severe liver disease including HCC, and can be used as a prediagnostic biomarker of HCC [24][25][26][27][28] . The predominant mutation in the precore region of HBV which involved a G-to-A change at nucleotide 1896, and resulted in a premature stop codon at codon 28, was proved to be associated with increased HCC risk [23,[28][29][30] .…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia

Utama¹,

Purwantomo

Siburian

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To identify the distribution of hepatitis B virus (HBV) subgenotype and basal core promoter (BCP) mutations among patients with HBV-associated liver disease in Indonesia. METHODS:Patients with chronic hepatitis (CH, n = 61), liver cirrhosis (LC, n = 62), and hepatocellular carcinoma (HCC, n = 48) were included in this study.HBV subgenotype was identified based on S or preS gene sequence, and mutations in the HBx gene including the overlapping BCP region were examined by direct sequencing. RESULTS:HBV genotype B (subgenotypes B2, B3, B4, B5 and B7) the major genotype in the samples, accounted for 75.4%, 71.0% and 75.0% of CH, LC and HCC patients, respectively, while the genotype C (subgenotypes C1, C2 and C3) was detected in 24.6%, 29.0%, and 25.0% of CH, LC, and HCC patients, respectively. Subgenotypes B3 (84.9%) and C1 (82.2%) were the main subgenotype in HBV genotype B and C, respectively. Serotype adw2 (84.9%) and adrq+ (89.4%) were the most prevalent in HBV genotype B and C, respectively. Double mutation (A1762T/G1764A) in the BCP was significantly higher in LC (59.7%) and HCC (54.2%) than in CH (19.7%), suggesting that this mutation was associated with severity of liver disease. The T1753V was also higher in LC (46.8%), but lower in HCC (22.9%) and CH (18.0%), suggesting that this mutation may be an indicator of cirrhosis. CONCLUSION:HBV genotype B/B3 and C/C1 are the major genotypes in Indonesia. Mutations in BCP, such as A1762T/G1764A and T1753V, might have an association with manifestations of liver disease.

show abstract

“…Base on the inclusion criteria, only 17 case-control studies (Sakamoto et al, 2006;Tanaka et al, 2006;Shinkai et al, 2007;Wang et al, 2007;Yuan et al, 2007;Zhang et al, 2007;Fang et al, 2008;Guo et al, 2008;Jang et al, 2008;Choi et al, 2009;Ja et al, 2009;Tangkijvanich et al, 2010;Welschinger et al, 2010;Zhu et al, 2010;Cho et al, 2011;Qu et al, 2011;Tatsukawa et al, 2011) with full-text were included in this meta-analysis and 18 studies were excluded. The flow chart of study selection is summarized in Figure 1.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

Hepatitis B Virus Gene C1653T Polymorphism Mutation and Hepatocellular Carcinoma Risk: an Updated Meta-analysis

Shi¹,

Zhang²,

Shang³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Although there have been many studies investigating possible associations between the C1653T mutation and risk of HCC, the results have been inconsistent. We conducted searches of the published literature in Pubmed and Embase databases up to January 2013. Seventeen studies with a total of 1,085 HCC cases and 1,365 healthy controls were retrieved.We found a significant association between the C1653T mutation and HCC risk (OR = 2.01, 95%CI= 1.49-2.70). In the subgroup analysis by ethnicity, a significant association was also found in Asians (OR = 2.07, 95%CI= 1.71-2.51). In subgroup analysis by HBV genotype, B and C were linked with development of HCC (B:OR = 2.21, 95%CI= 1.13-4.34; C:OR = 2.26, 95%CI= 1.61-3.16). However, no significant association was found between the C1653T mutation and HCC risk in HBeAg positive cases. In conclusion, this meta-analysis suggests that the C1653T mutation may be associated with susceptibility to HCC.

show abstract

Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma

Cited by 119 publications

References 44 publications

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma

A case–control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma

Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia

Hepatitis B Virus Gene C1653T Polymorphism Mutation and Hepatocellular Carcinoma Risk: an Updated Meta-analysis

Contact Info

Product

Resources

About